Oncolytics Biotech Inc
TSX:ONC
Oncolytics Biotech Inc
Cash from Operating Activities
Oncolytics Biotech Inc
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oncolytics Biotech Inc
TSX:ONC
|
Cash from Operating Activities
-CA$24.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Cash from Operating Activities
-CA$1.9m
|
CAGR 3-Years
37%
|
CAGR 5-Years
-113%
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Cash from Operating Activities
$7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Cash from Operating Activities
$92.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Cash from Operating Activities
-$231.4m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-83%
|
CAGR 10-Years
-48%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Cash from Operating Activities
-CA$9.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
|
Oncolytics Biotech Inc
Glance View
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta and currently employs 26 full-time employees. The company went IPO on 2000-06-01. The firm is focused on the discovery and development of pharmaceutical products for the treatment of cancers. Its lead product, Pelareorep, is a systemically administered immuno-oncology (I-O) viral agent with the potential to treat a variety of cancers. Pelareorep’s anti-tumor activity is based on three modes: selective viral replication in permissive cancer cells, which leads to tumor cell lysis; activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells; and specific adaptive immune response triggered by tumor and viral-associated antigens displayed by antigen presenting cells (APCs), infected tumor cells and dendritic cells to T cells.
See Also
What is Oncolytics Biotech Inc's Cash from Operating Activities?
Cash from Operating Activities
-24.6m
CAD
Based on the financial report for Jun 30, 2025, Oncolytics Biotech Inc's Cash from Operating Activities amounts to -24.6m CAD.
What is Oncolytics Biotech Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-5%
Over the last year, the Cash from Operating Activities growth was 7%. The average annual Cash from Operating Activities growth rates for Oncolytics Biotech Inc have been -2% over the past three years , -2% over the past five years , and -5% over the past ten years .
You don't have any saved screeners yet